12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IMA901: Completed Phase III enrollment

immatics completed enrollment of about 345 patients in the open-label, international Phase III IMPRINT trial comparing intradermal IMA901 plus Sutent sunitinib vs. Sutent alone. Pfizer...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >